IgHy10 is developed by University Hospital, Lille.

What development phase is IgHy10 in?

IgHy10 is FDA-approved (marketed).

Last reviewed 2026-04-20 · How we verify

IgHy10

University Hospital, Lille · FDA-approved active Small molecule Quality 0/100

At a glance

Generic name	IgHy10
Also known as	HyQvia
Sponsor	University Hospital, Lille
Modality	Small molecule
Phase	FDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

IgG Level in Primary Immunodeficiency Switching From Standard SCIG to Every Other Week HyQvia (PHASE4)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

IgHy10 CI brief — competitive landscape report
IgHy10 updates RSS · CI watch RSS
University Hospital, Lille portfolio CI